First, although the molecular mechanisms of the RBM38–lncRNA–GAS5 pathway underlying sorafenib resistance in HCC cells were elucidated via in vitro and in vivo experiments, further clinical verification is required in primary samples from patients with sorafenib-resistant HCC. This evidence concerns the gene RBM38 and hepatocellular carcinoma.